Denali Therapeutics Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of stroke, gout, multiple sclerosis, Alzheimer's disease, hypertension, silicosis, graft-versus-host disease and nonalcoholic steatohepatitis (NASH).